AstraZeneca leukemia drug Calquence gets USFDA okay Medical Dialogues Bureau24 Nov 2019 4:30 AM GMTNew Delhi: AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go-ahead for the company's Calquence drug...
BeiGene gets USFDA approval for lymphoma drug Brukinsa Medical Dialogues Bureau17 Nov 2019 3:50 AM GMTBeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21%...
AbbVie says multiple parties vying for assets related to Allergan deal approval Medical Dialogues Bureau4 Nov 2019 3:30 AM GMTAbbVie Inc said it had notified the U.S. antitrust watchdog of its intention to divest its experimental inflammatory bowel disease therapy,...
Allergan shareholders okays USD 63 billion AbbVie acquisition Medical Dialogues Bureau15 Oct 2019 4:00 AM GMTUnder the terms of the agreement announced on June 25, 2019, AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity...
AbbVie wins USFDA nod for new rheumatoid arthritis drug priced at Rs 41 lakh per year Medical Dialogues Bureau18 Aug 2019 4:06 AM GMTA four-week supply of Humira, the world's best-selling medicine, has a list price of about $5,174, amounting to more than $60,000 for a year.U.S:...
Abbvie finalizes deal to buy Botox maker Allergan for $63 billion Medical Dialogues Bureau26 Jun 2019 4:30 AM GMTA note from Moody's affirmed Abbvie's debt rating, saying a plan to reduce debt through existing blockbusters like AbbVie's Humira and Imbruvica and...
AbbVie wins USFDA nod for Mavyret to treat HCV genotypes in pediatric patients Farhat Nasim3 May 2019 3:40 AM GMTNew Delhi: AbbVie Inc. recently won the U.S. Food and Drug Administration (USFDA) approval for Mavyret (glecaprevir and pibrentasvir) tablets to treat...
USFDA puts partial hold on Abbvie Venclexta clinical trials after deaths Farhat Nasim21 March 2019 4:15 AM GMTThe clinical hold does not impact any of the approved indications for Venclexta, such as chronic lymphocytic leukaemia (CLL) or acute myeloid...
Abbvie to record $4 billion impairment charges on Stemcentrx assets Medical Dialogues Bureau6 Jan 2019 3:30 AM GMTThe drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid...
Lupin and AbbVie announces partnership to develop, commercialize Novel Oncology Drug Medical Dialogues Bureau24 Dec 2018 4:00 AM GMTMumbai: Pharma major Lupin and global biopharmaceutical company AbbVie Inc., announced that AbbVie has licensed Lupin's MALT1 (Mucosa-Associated...
AbbVie wins US trial in lawsuit over AndroGel's risks Medical Dialogues Bureau29 Jan 2018 4:00 AM GMTA federal jury in Chicago found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the...
Roche, AbbVie leukemia drug superior to older medicine in study Ruby Khatun Khatun24 Nov 2017 4:15 AM GMTPatients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without...
